Drug Targeting Complexity: Tissue-Specific Regulation and Molecular Paradigms in Cancer Therapy presents a rigorous examination of advanced strategies for the selective targeting of neoplastic cells and their distinct microenvironments. This comprehensive volume elucidates both tissue-specific and tumor-specific molecular targets, clarifying how these methodologies can significantly enhance therapeutic precision while mitigating off-target effects. The initial section of the text provides an in-depth analysis of tissue-specific regulatory targets across various organs, including the liver, lungs, brain, skin, and bones. It delineates the critical mediators and mechanisms that govern tumor immunity, thereby identifying novel therapeutic avenues.
Each chapter meticulously evaluates key regulatory molecules such as TGF-β, CTLA-4, and IL-10, exploring their roles in tumorigenesis and the potential for targeted interventions across a spectrum of malignancies. Subsequent sections focus on tumor tissue-specific molecular targets, encompassing immunological checkpoints, growth factors, and signaling pathways pertinent to cancers of the liver, stomach, ovary, prostate, and colon. The text provides insights into the application of monoclonal antibodies and molecular inhibitors as strategies to impede cancer progression and address therapeutic resistance. Concluding chapters address emerging therapeutic paradigms, including precision medicine and nanotechnology.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. List of contributors - p. xi 7. Part I: Tissue-specific targets - p. P1 8. Chapter 1. Brain-specific regulatory T cell mediators - p. 3 9. Chapter 2. Liver-specific regulatory T cell mediators - p. 41 10. Chapter 3. Lung-specific regulatory T cell mediators - p. 59 11. Chapter 4. Adrenal gland-specific regulatory T cell mediators - p. 83 12. Chapter 5. Lymph node–specific regulatory T cell mediators - p. 109 13. Chapter 6. Skin-specific regulatory T cell mediators - p. 129 14. Chapter 7. Bone-specific regulatory T cell mediators - p. 153 15. Chapter 8. Colon-specific regulatory T cell mediators: Foxp3+ CD4, CTLA-4, CD3, CD25, CD127, CD45RA - p. 179 16. Chapter 9. Breast-specific regulatory T cell mediators - p. 207 17. Part II: Tumor tissue-specific targets - p. P2 18. Chapter 10. Molecular targets in liver cancer - p. 233 19. Chapter 11. Molecular targets for gastric cancer - p. 267 20. Chapter 12. Role of molecular target therapies in effective breast cancer treatments - p. 287 21. Chapter 13. Molecular targets in ovarian cancer - p. 323 22. Chapter 14. Molecular targets in prostate cancer - p. 355 23. Chapter 15. Molecular targets in colon cancer - p. 393 24. Chapter 16. Molecular targets in lung cancer - p. 421 25. Chapter 17. Molecular targets in blood cancer - p. 453 26. Part III: Advanced therapeutic approaches - p. P3 27. Chapter 18. Human genetic mutations as cancer drivers and drug targets: advances in cancer genomics - p. 477 28. Chapter 19. Microbiome in cancer immunotherapy and cancer progression - p. 505 29. Chapter 20. Advances in precision medicine: tissue-specific drug delivery and molecular pathways in cancer treatment - p. 533 30. Chapter 21. Future directions and challenges in the field of cancer targeting therapies - p. 575 31. Index - p. 605
Drug Targeting Complexity: Tissue-Specific Regulation and Molecular Paradigms in Cancer Therapy presents a rigorous examination of advanced strategies for the selective targeting of neoplastic cells and their distinct microenvironments. This comprehensive volume elucidates both tissue-specific and tumor-specific molecular targets, clarifying how these methodologies can significantly enhance therapeutic precision while mitigating off-target effects. The initial section of the text provides an in-depth analysis of tissue-specific regulatory targets across various organs, including the liver, lungs, brain, skin, and bones. It delineates the critical mediators and mechanisms that govern tumor immunity, thereby identifying novel therapeutic avenues.
Each chapter meticulously evaluates key regulatory molecules such as TGF-β, CTLA-4, and IL-10, exploring their roles in tumorigenesis and the potential for targeted interventions across a spectrum of malignancies. Subsequent sections focus on tumor tissue-specific molecular targets, encompassing immunological checkpoints, growth factors, and signaling pathways pertinent to cancers of the liver, stomach, ovary, prostate, and colon. The text provides insights into the application of monoclonal antibodies and molecular inhibitors as strategies to impede cancer progression and address therapeutic resistance. Concluding chapters address emerging therapeutic paradigms, including precision medicine and nanotechnology.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. List of contributors - p. xi 7. Part I: Tissue-specific targets - p. P1 8. Chapter 1. Brain-specific regulatory T cell mediators - p. 3 9. Chapter 2. Liver-specific regulatory T cell mediators - p. 41 10. Chapter 3. Lung-specific regulatory T cell mediators - p. 59 11. Chapter 4. Adrenal gland-specific regulatory T cell mediators - p. 83 12. Chapter 5. Lymph node–specific regulatory T cell mediators - p. 109 13. Chapter 6. Skin-specific regulatory T cell mediators - p. 129 14. Chapter 7. Bone-specific regulatory T cell mediators - p. 153 15. Chapter 8. Colon-specific regulatory T cell mediators: Foxp3+ CD4, CTLA-4, CD3, CD25, CD127, CD45RA - p. 179 16. Chapter 9. Breast-specific regulatory T cell mediators - p. 207 17. Part II: Tumor tissue-specific targets - p. P2 18. Chapter 10. Molecular targets in liver cancer - p. 233 19. Chapter 11. Molecular targets for gastric cancer - p. 267 20. Chapter 12. Role of molecular target therapies in effective breast cancer treatments - p. 287 21. Chapter 13. Molecular targets in ovarian cancer - p. 323 22. Chapter 14. Molecular targets in prostate cancer - p. 355 23. Chapter 15. Molecular targets in colon cancer - p. 393 24. Chapter 16. Molecular targets in lung cancer - p. 421 25. Chapter 17. Molecular targets in blood cancer - p. 453 26. Part III: Advanced therapeutic approaches - p. P3 27. Chapter 18. Human genetic mutations as cancer drivers and drug targets: advances in cancer genomics - p. 477 28. Chapter 19. Microbiome in cancer immunotherapy and cancer progression - p. 505 29. Chapter 20. Advances in precision medicine: tissue-specific drug delivery and molecular pathways in cancer treatment - p. 533 30. Chapter 21. Future directions and challenges in the field of cancer targeting therapies - p. 575 31. Index - p. 605
